Dinaciclib prolongs survival in the LSL-Kras(G12D/+); LSL-Trp53(R172H/+); Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma

Dinaciclib is a small molecule cyclin-dependent kinase inhibitor with the potential to treat multiple cancers. To better understand its cytotoxic action in pancreatic ductal adenocarcinoma (PDAC), we evaluated dinaciclib therapeutic effects in the transgenic mouse model (LSL-Kras(G12D/+); LSL-Trp53(...

Full description

Saved in:
Bibliographic Details
Published in:Am J Transl Res
Main Authors: Yang, Jia, Hu, Su, Shangguan, Junjie, Eresen, Aydin, Li, Yu, Ma, Quanhong, Yaghmai, Vahid, Benson III, Al B, Zhang, Zhuoli
Format: Artigo
Language:Inglês
Published: e-Century Publishing Corporation 2020
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7137051/
https://ncbi.nlm.nih.gov/pubmed/32269732
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items